AIM: The aim of this study was to analyze the clinicopathological characteristics of TMPRSS2 and KLK11 gene expression levels in human prostate cancer (PCa), and to evaluate their clinical significance in the progression of PCa. METHODS: The expression of prostate-type and brain-type isoforms of KLK11 gene, and TMPRSS2 gene was analyzed by quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) in 63 PCa tissues. The correlation of TMPRSS2 and KLK11 gene expression with the clinicopathological characteristics and with the prognosis of PCa was subsequently assessed. RESULTS: The mean values of TMPRSS2 (3.91 +/- 0.78 in PCa vs. 0.26 +/- 0.04 in normal prostate tissues) and both isoforms of KLK11 (prostate-type: 3.63 +/- 0.42 in PCa vs. 0.49 +/- 0.07 in normal prostate tissues; brain-type: 3.11 +/- 0.30 in PCa vs. 0.46 +/- 0.05 in normal prostate tissues) were significantly higher in cancer tissues compared with their normal counterparts. We found a significant positive correlation between TMPRSS2 expression and tumor stage (P = 0.02), Gleason score (P = 0.008), and tumor grade (P = 0.016). Regarding prostate-type KLK11, we identified a significant association between lower expression and higher tumor stage (P = 0.009), Gleason score (P = 0.01), and tumor grade (P = 0.006). No such association was seen with the brain-type isoform. The survival rate of the patients with TMPRSS2-high/KLK11-low expression was lowest (P = 0.003). CONCLUSION: The results suggest that the up-regulation of TMPRSS2 gene and the down-regulation of KLK11 gene in advanced and more aggressive tumors may open the feasibility of being used as biomarkers distinguishing the tumor aggressiveness as well as novel prognostic indicators for PCa.
AIM: The aim of this study was to analyze the clinicopathological characteristics of TMPRSS2 and KLK11 gene expression levels in humanprostate cancer (PCa), and to evaluate their clinical significance in the progression of PCa. METHODS: The expression of prostate-type and brain-type isoforms of KLK11 gene, and TMPRSS2 gene was analyzed by quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) in 63 PCa tissues. The correlation of TMPRSS2 and KLK11 gene expression with the clinicopathological characteristics and with the prognosis of PCa was subsequently assessed. RESULTS: The mean values of TMPRSS2 (3.91 +/- 0.78 in PCa vs. 0.26 +/- 0.04 in normal prostate tissues) and both isoforms of KLK11 (prostate-type: 3.63 +/- 0.42 in PCa vs. 0.49 +/- 0.07 in normal prostate tissues; brain-type: 3.11 +/- 0.30 in PCa vs. 0.46 +/- 0.05 in normal prostate tissues) were significantly higher in cancer tissues compared with their normal counterparts. We found a significant positive correlation between TMPRSS2 expression and tumor stage (P = 0.02), Gleason score (P = 0.008), and tumor grade (P = 0.016). Regarding prostate-type KLK11, we identified a significant association between lower expression and higher tumor stage (P = 0.009), Gleason score (P = 0.01), and tumor grade (P = 0.006). No such association was seen with the brain-type isoform. The survival rate of the patients with TMPRSS2-high/KLK11-low expression was lowest (P = 0.003). CONCLUSION: The results suggest that the up-regulation of TMPRSS2 gene and the down-regulation of KLK11 gene in advanced and more aggressive tumors may open the feasibility of being used as biomarkers distinguishing the tumor aggressiveness as well as novel prognostic indicators for PCa.
Authors: Christopher H Chay; Carlton R Cooper; James D Gendernalik; Saravana M Dhanasekaran; Arul M Chinnaiyan; Mark A Rubin; Alvin H Schmaier; Kenneth J Pienta Journal: Urology Date: 2002-11 Impact factor: 2.649
Authors: Carla A Borgoño; Stefano Fracchioli; George M Yousef; Irene A Rigault de la Longrais; Liu-Ying Luo; Antoninus Soosaipillai; Manuela Puopolo; Linda Grass; Andreas Scorilas; Eleftherios P Diamandis; Dionyssios Katsaros Journal: Int J Cancer Date: 2003-09-10 Impact factor: 7.396
Authors: George M Yousef; Carsten Stephan; Andreas Scorilas; Mohamed Abd Ellatif; Klaus Jung; Glen Kristiansen; Monika Jung; Mary-Ellen Polymeris; Eleftherios P Diamandis Journal: Prostate Date: 2003-09-01 Impact factor: 4.104
Authors: Ya-Wen Chen; Ming-Shyue Lee; Amanda Lucht; Feng-Pai Chou; Wei Huang; Thomas C Havighurst; KyungMann Kim; Jehng-Kang Wang; Toni M Antalis; Michael D Johnson; Chen-Yong Lin Journal: Am J Pathol Date: 2010-04-09 Impact factor: 4.307
Authors: S A Krieg; X Fan; Y Hong; Q-X Sang; A Giaccia; L M Westphal; R B Lathi; A J Krieg; N R Nayak Journal: Mol Hum Reprod Date: 2012-04-14 Impact factor: 4.025
Authors: K Mwamukonda; Y Chen; L Ravindranath; B Furusato; Y Hu; J Sterbis; D Osborn; I Rosner; I A Sesterhenn; D G McLeod; S Srivastava; G Petrovics Journal: Prostate Cancer Prostatic Dis Date: 2009-07-14 Impact factor: 5.554
Authors: David L Kolin; Keiyan Sy; Fabio Rotondo; Mena N Bassily; Kalman Kovacs; Christine Brezden-Masley; Catherine J Streutker; George M Yousef Journal: Tumour Biol Date: 2015-07-30
Authors: Mikhail G Dozmorov; Joseph T Azzarello; Jonathan D Wren; Kar-Ming Fung; Qing Yang; Jeffrey S Davis; Robert E Hurst; Daniel J Culkin; Trevor M Penning; Hsueh-Kung Lin Journal: BMC Cancer Date: 2010-12-06 Impact factor: 4.430
Authors: Thomas Kryza; Lakmali M Silva; Nathalie Bock; Ruth A Fuhrman-Luck; Carson R Stephens; Jin Gao; Hema Samaratunga; Mitchell G Lawrence; John D Hooper; Ying Dong; Gail P Risbridger; Judith A Clements Journal: Mol Oncol Date: 2017-08-10 Impact factor: 6.603